Climb Bio to provide budoprutug development strategy at virtual investor event

Climb Bio will be hosting a virtual investor event October 15, 2024. The event will feature members of Climb Bio’s management team who will provide an update on the Company’s development strategy for budoprutug, an anti-CD19 monoclonal antibody with potential to treat a broad range of B-cell mediated diseases. Event Highlights: The Company’s strategic approach to developing budoprutug will consider indications across three opportunity sets; The Company will share data supporting budoprutug’s potential for deep and durable depletion of both peripheral and tissue-resident B-cells in patients with immune-mediated diseases ; The Company plans to continue to advance the subcutaneous formulation clinical program, with non-clinical data expected in the first half of 2025; Additional promising Phase 1b Study Results in pMN; Initiation of Phase 1b clinical trial in SLE planned for the first half of 2025, subject to regulatory clearance; Initiation of Phase 2 clinical trial in ITP planned for the first half of 2025, subject to regulatory clearance.